By October 21, 2011, five out of 12 subjects have completed the long-term follow-up portion of our Swiss study of LSD-assisted psychotherapy for anxiety associated with advanced-stage illness. These long-term …
On May 26, 2011, the 12th and final subject was treated in MAPS’ Swiss study of LSD-assisted psychotherapy for anxiety associated with advanced-stage illness. Once we collect follow-up data from …
On May 3, 2011, our clinical research team submitted to the FDA the annual report for our nearly-completed Swiss study of LSD-assisted psychotherapy for anxiety associated with advanced life-threatening …
From February 17-19, 2011, in yet another stop on her whirlwind international tour, MAPS Clinical Research Associate Berra Yazar-Klosinski, Ph.D., met with Clinical Investigator Peter Gasser, M.D., in …
On January 11, 2011, our clinical team announced that the twelfth and final subject passed the screening process and was enrolled in our Swiss study of LSD-assisted psychotherapy for anxiety associated …
The twelfth and final subject in MAPS’ study of LSD-assisted psychotherapy to treat anxiety associated with life-threatening illnesses is now in the screening process. The study is taking place in …
On Sept. 29, we wired $10,000 USD in grant money to help fund a British study that aims to discover how psilocybin works in the brain. The study investigators, Robin Carhart-Harris, Ph.D., Richard Wise, …
The Swiss IRB approved two new subjects for our LSD study (subjects #10 and #11) who have anxiety related to their disease which will likely reduce their lifespan, although their condition is not likely …
Click here to access the investigator’s brochure (or “IB”) for psilocybin commissioned by MAPS and intended to be submitted to FDA and institutional review boards or ethics boards. The IB …
Beginning on June 28, MAPS clinical volunteer research intern Tim Whalen has been building a database to house data from our Swiss study of LSD-assisted psychotherapy for the treatment of anxiety associated …
Location: Solothurn, Switzerland MAPS is proud to sponsor the first study of the therapeutic use of LSD in humans in over 35 years. This study, based in Switzerland, investigates the safety and effectiveness …
On May 25, 2010, the Swiss Ethics Committee approved our amendment to the original LSD protocol that will allow us to make audio and video recordings of the therapy sessions. These recordings will be available …
